Journal article icon

Journal article

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.

Abstract:

BACKGROUND: AQ4N (1,4-bis[[2-(dimethylamino)ethyl] amino]-5,8-dihydroxyanthracene-9, 10-dione bis-N-oxide dihydrochloride) is a prodrug which is selectively activated within hypoxic tissues to AQ4, a topoisomerase II inhibitor and DNA intercalator. PATIENTS AND METHODS: In the phase I study, 22 patients with oesophageal carcinoma received an i.v. infusion of AQ4N (22.5-447 mg/m(2)) followed, 2 weeks later, by further infusion and radiotherapy. Pharmacokinetics and lymphocyte AQ4N and AQ4 leve...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mdm120

Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO More from this journal
Volume:
18
Issue:
6
Pages:
1098-1103
Publication date:
2007-06-01
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Language:
English
Keywords:
Pubs id:
pubs:119992
UUID:
uuid:d07a85fb-04a5-44c4-be8f-f8e3c384619a
Local pid:
pubs:119992
Source identifiers:
119992
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP